Login to Your Account

Other News To Note

Tuesday, January 25, 2011
Polyplus-transfection SA, of Strasbourg, France, said it has granted Roche Glycart AG, a Swiss biotechnology company fully owned by Roche, a nonexclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes. The license will enable Roche Glycart AG to use PEI in its research to produce antibody-based products.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription